GlassScriptPhysician profile
Jamie M Bright
NPI 1245632637
$3,141.98
in general payments reported to CMS, 2019-2025
34 companies · $840 in 2025
The $840 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $230 · 2022: $421 · 2023: $744 · 2024: $907 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,490.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $613.62 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $570.40 | 2021-2025 | |
| Glaxosmithkline, LLC. | $253.94 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $184.37 | 2023-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $155.97 | 2022-2023 | |
| Lundbeck LLC | $153.72 | 2022-2025 | Vyepti |
| Lilly USA, LLC | $110.33 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $99.81 | 2023-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $80.48 | 2022-2023 | |
| Dexcom, INC. | $78.85 | 2023-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $78.51 | 2022-2025 | Breztri, Airsupra |
| Pfizer INC. | $73.97 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.76 | 2021-2025 | Xifaxan |
| Inogen, INC. | $58.55 | 2022-2023 | Inogen At Home Stationary Concentrator |
| Amgen INC. | $57.09 | 2022-2025 | Otezla, Repatha, Krystexxa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $47.70 | 2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $47.22 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.09 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $44.36 | 2022-2023 | Camzyos |
| Amarin Pharma, INC. | $37.76 | 2021 | |
| Sumitomo Pharma America, INC. | $36.17 | 2023 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $33.06 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.59 | 2021-2022 | |
| Alkermes, INC. | $28.64 | 2023 | Lybalvi |
| Esperion Therapeutics, INC. | $20.29 | 2021 | |
| Philips North America LLC | $19.89 | 2024 | (Ck7) Extended Holter |
| Axsome Therapeutics, INC. | $19.28 | 2025 | Auvelity |
| Nestle Healthcare Nutrition INC. | $17.33 | 2022 | |
| Ardelyx, INC. | $17.29 | 2024 | Ibsrela |
| Biohaven Pharmaceutical Holding Company LTD. | $16.77 | 2022 | |
| Antares Pharma, INC. | $15.23 | 2024 | Xyosted |
| Corcept Therapeutics | $14.54 | 2025 | Korlym |
| Dynavax Technologies Corporation | $13.44 | 2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $6.96 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Bright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.